期刊文献+

FIG-ROS融合基因在肝内胆管细胞癌中表达及其意义 被引量:6

Expression of FIG-ROS fusion gene in intrahepatic cholangiocarcinoma and its significance
原文传递
导出
摘要 目的:探讨FIG-ROS融合基因在肝内胆管细胞癌(ICC)细胞中的表达,以及对其干预后ICC细胞的生物学行为的变化。方法:用Western blot法检测4份不同ICC组织样本及3种ICC细胞株(HUCCT1、REB、QBC939)中ROS蛋白的表达;选择ROS阳性ICC细胞,用一系列表达不同序列ROS-sh RNA与FIG-sh RNA的质粒分别转染该细胞后,用Western blot检测ROS和FIG蛋白表达;选择对ROS和FIG表达抑制作用最强的ROS-sh RNA与FIG-sh RNA序列分别或联合转染上述细胞后,观察细胞增殖、细胞周期、凋亡及集落形成情况。结果:2份ICC组织样本与1个细胞株(HUCCT1)呈ROS阳性表达;转染ROS1-6290 sh RNA和FIG-363 sh RNA对HUCCT1细胞ROS与FIG蛋白表达的抑制作用最强。与未转染的HUCCT1细胞比较,单独转染FIG-363 sh RNA对细胞增殖、凋亡及细胞周期无明显影响(均P>0.05),但能明显减少细胞集落形成(P<0.05);ROS1-6290 sh RNA单独或联合FIG-363 sh RNA转染均能明显抑制细胞增殖、诱导细胞凋亡与细胞周期阻滞、减少细胞集落形成,且联合转染的效应更为明显(均P<0.05)。结论:部分ICC存在FIG-ROS融合基因表达,对两种基因的联合抑制可能是靶向治疗该类ICC的有效途径。 Objective: To investigate the expression of FIG-ROS fusion gene in intrahepatic cholangiocarcinoma(ICC) cells and the effects of its intervention on biological behavior of ICC cells.Methods: ROS protein expression in 4 different specimens of ICC tissue and 3 types of ICC cell line(HUCCT1, REB and QBC939) was determined by Western blot analysis; the ROS positive cell line was selected for use and after transfection with a series of plasmids containing different sequences of ROS-sh RNAs or FIG-sh RNAsrespectively, the protein expressions of ROS and FIG in the cells were measured by Western blot analysis. The sequences of ROS-sh RNA and FIG-sh RNA with highest inhibitory effect on ROS and FIG expression were chosen, which were alone or in combination transfected into the above cells, and after that, the cell proliferation, apoptosis, cell cycle and colony formation were observed.Results: Two specimens of ICC tissue and one ICC cell line(HUCCT1) showed positive ROS expression. Transfection of ROS1-6290 sh RNA and FIG-363 sh RNA had the most remarkable inhibitory effect on ROS and FIG expression, respectively. Compared with the HUCCT1 cells without any transfection, lone FIG-363 sh RNA transfection had no obvious effect on proliferation, apoptosis or cell cycle phase(all P〉0.05), but significantly reduced the colony formation of the cells(P〈0.05); either ROS1-6290 sh RNA transfection alone or in combination with FIG-363 sh RNA showed significant effects of suppression of proliferation, induction of apoptosis and cell cycle arrest and inhibition of colony formation, and these effects were more remarkable in cells with combined transfection(all P〈0.05). Conclusion: Some kinds of ICC have FIG-ROS fusion gene expression, and the combined inhibition of the two genes may probably provide a hopeful targeted treatment approach for these ICC.
出处 《中国普通外科杂志》 CAS CSCD 北大核心 2015年第2期199-205,共7页 China Journal of General Surgery
基金 湖南省科学技术厅科技计划资助项目(2014SK3071)
关键词 胆管肿瘤 胆管 肝内 原癌基因 癌基因融合 Bile Duct Neoplasms Bile Ducts Intrahepatic Proto-Oncogenes Oncogene Fusion
  • 相关文献

参考文献21

  • 1McLean L, Patel T. Racial and ethnic variations in the epidemiology of intralaepatic cholangiocarcinoma in the United States[J]. Liver Int, 2006, 26(9): 1047-1053. 被引量:1
  • 2Khan SA, Davidson BR, Goldin R, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document[J]. Gut, 2002, 51 Suppl 6:VI 1-9. 被引量:1
  • 3Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection[J]. Ann Surg, 2008, 248(1):84-96. 被引量:1
  • 4Donatella Marino,Federica Colombi,Dario Ribero,Massimo Aglietta,Francesco Leone,王卓路(编译),李新营(编译).如何改善靶向药物在胆管癌中的疗效?[J].中国普通外科杂志,2013,22(8):973-975. 被引量:1
  • 5Ong CK, Subimerb C, Pairojkul C, et al. Exome sequencing of liver fluke-associated cholangiocarcinoma[J]. Nat Genet, 2012, 44(6): 690-693,. 被引量:1
  • 6Gu TL, Deng X, Huang F, et al. Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma[J]. PLoSOne, 2011, 6(1):e15640. doi: 10.1371/joumal.pone.O015640. 被引量:1
  • 7Charest A, Lane K, McMahon K, et al. Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21) [J]. Genes Chromosomes Cancer, 2003, 37(1):58- 71. 被引量:1
  • 8Saborowski A, Saborowski M, Davare MA, et al. Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target[J]. Proc Natl Acad Sci U S A, 2013, 110(48): 19513-19518. 被引量:1
  • 9Shaw AT, Camidge DR, Engelman JA, et al. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS 1 gene rearrangement[C]//ASCO Meet Abstr (2012) 30(I 5 Suppl):7508. doi: 10.1097/CCO.0b013e32835d8175. 被引量:1
  • 10Malhi H, Gores GJ. Cholangiocarcinoma: modern advances in understanding a deadly old disease[J]. J Hepatol, 2006, 45(6): 856- 867. 被引量:1

二级参考文献15

  • 1Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14):1273-1281. 被引量:1
  • 2Sharma A, Dwary AD, Mohanti BK, et al. Best supportive care compared with chemotherapy for unreseetable gall bladder cancer: a randomized controlled study[J]. J Clin Oncol, 2010, 28(30):4581-4586. 被引量:1
  • 3Marino D, Leone F, Cavalloni G, et al. Biliary tract carcinomas: from chemotherapy to targeted therapy[J]. Crit Rev Oncol Hematol, 2012, 85(2):136-148. 被引量:1
  • 4Leone F, Cavalloni G, Pignochino Y, et al. Somatic mutationsof epidermal growth factor rec.eptor in bile duet and gallbladder carcinoma[J]. Clin Cancer Res, 2006, 12(6): 1680-1685. 被引量:1
  • 5Gruenberger B, Schueller J, Heubrandtner U, et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study[J]. Lancet OncoI, 2010, 11(12):1142-1148. 被引量:1
  • 6Jenscn LH, Lindebjerg J, Plocn J, et al. Phase II marker- driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tracl cancer[J]. Ann Oncol, 2012, 23(9):2341-2346. 被引量:1
  • 7Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without crlotinib in advanced biliary- tract cancer: a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol, 2012, 13(2):181-188. 被引量:1
  • 8Malka D, Fartoux L, Rousseau V, el al. Gemcitabine and oxaliplatin (GEMOX) alone or in combination with eetuximab as first-line treatment for advanced biliary cancer: Final analysis of a randomized phase II trial (BINGO) [J]. J Clin Oneol, 2012, 30 (suppl, abstr 4032). 被引量:1
  • 9Philip PA, Mahuney MR, Allmer C, et al. Phase I1 study of erlotinib in patients with advanced biliary cancer[J]. J Clin Oncol, 2006, 24(19):3069-3074. 被引量:1
  • 10Moore M J, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabinc alone in patients with advanced pancreatic cancer: a phase II1 trial of the National Cancer Institute of Canada Clinical Trials Group[J]. J Clin Oncol, 2007, 25(15):1960-1966. 被引量:1

同被引文献79

  • 1郑军,朱耀明,邹声泉,吴高松.原癌基因c-erbB-2在胆管癌细胞中的表达[J].肿瘤防治研究,2007,34(6):462-463. 被引量:1
  • 2Matsushime H, Wang LH, Shibuya M. Human c-ros-1 gene homologous to the v-ros sequence of UR2 sarcoma virus encodes for a transmembrane receptorlike molecule[J]. Mol Cell Biol, 1986, 6(8):3000-3004. 被引量:1
  • 3Birchmeier C, Birnbaum D, Waitches G, et al. Characterization of an activated human ros gene[J]. Mol Cell Biol, 1986, 6(9):3109-3116. 被引量:1
  • 4Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome[J]. Oncogene, 2000, 19(49):5548-5557. 被引量:1
  • 5Acquaviva J, Wong R, Charest A. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer[J]. Biochim Biophys Acta, 2009, 1795(1):37-52. 被引量:1
  • 6Rimkunas VM, Crosby KE, Li D, et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion[J]. Clin Cancer Res, 2012, 18(16): 4449-4457. 被引量:1
  • 7El-Deeb IM, Yoo KH, Lee SH. ROS receptor tyrosine kinase: a new potential target for anticancer drugs[J]. Med Res Rev, 2011, 31(5): 794-818. 被引量:1
  • 8Sonnenberg-Riethmacher E, Walter B, Riethmacher D, et al. The c-ros tyrosine kinase receptor controls regionalization and differentiation of epithelial cells in the epididymis[J]. Genes Dev, 1996, 10(10):1184-1193. 被引量:1
  • 9Xiong Q, Chan JL, Zong CS, et al. Two chimeric receptors of epidermal growth factor receptor and c-Ros that differ in their transmembrane domains have opposite effects on cell growth[J]. Mol Cell Biol, 1996, 16(4):1509-1518. 被引量:1
  • 10Zong CS, Zeng L, Jiang Y, et al. Stat3 plays an important role in oncogenic Ros- and insulin-like growth factor I receptor-induced anchorage-independent growth[J]. J Biol Chem, 1998, 273(43):28065-28072. 被引量:1

引证文献6

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部